update

Biotrial criticised over fatal Phase I study by France's social affairs inspectorate

By Gareth Macdonald contact

- Last updated on GMT

iStock/ewg3D
iStock/ewg3D

Related tags: Clinical trial

French investigators reviewing the Phase I trial in which one volunteer died and five others were hospitalized in January have criticised CRO Biotrial over how it conducted the study.

France's social affairs inspectorate (IGAS) published its report (here​ – in French) today, explaining that the protocol approved by ANSM – the national drug safety agency – was not at fault.

Instead the inspectorate said the way it was implemented by Rennes-based Biotrial was flawed, accusing the contract research organisation (CRO) of major shortcomings in its management of the study.

These failings included that Biotrial continued to administer the drug to volunteers in the cohort after the first member of the group was sent to hospital and that it failed to confirm patient consent before beginning the study.

Communication breakdown

The IGAS reviewers also said Biotrial and Bial – the Portugal-based drug company that developed BIA 10-2474 – did not inform French health authorities of the adverse events in a timely manner.

The first volunteer was admitted to hospital on January 10 suffering neurological symptoms. However, according to the report, Biotrial and Bial did not inform authorities until January 14.

They also said the companies failed to implement enhanced monitoring of participants after the study was halted on January 11.

Biotrial has previously denied any wrong doing. The firm did not respond to a request for comment.

French Health Minister Marisol Touraine will present IGAS' findings today.

UPDATE:

In an official statement released this afternoon Biotrial said it was shocked by the conclusions detailed in the report.

Biotrial deplores this situation, especially since it has always strictly respected the test protocol validated by the ANSM, and that it has been shown that it is the Portuguese Laboratory Bial’s compound, by it unexpected and unpredictable toxicity, which is at fault for the accident.​"

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars